Diagnostics, Inc. (NYSE:DGX) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement.
As previously reported, ERBA Diagnostics, Inc. (the
Company), has a secured, revolving credit facility of up
to $5,000,000 with Citibank, N.A. (Citibank), to those
certain Business Loan Agreement and amended and restated
Promissory Note (the Old Note). As previously reported,
the maturity date of the Old Note is December 31, 2016.
On December 27, 2016, the Company entered into an amended and
restated Promissory Note (the Amended and Restated Note)
with Citibank, such that the maturity date of such secured,
revolving credit facility has been extended from December 31,
2016 to June 30, 2017. Other than the extension of the maturity
date of the secured, revolving credit facility, the terms and
conditions of the secured, revolving credit facility, including,
without limitation, the annual interest rate equal to the 30-day
LIBOR plus 1.75%, remain the same. All other agreements
associated with the secured, revolving credit facility remain
unchanged and outstanding.
The description of the Amended and Restated Note set forth under
this Item 1.01 does not purport to be complete. Such description
is qualified in its entirety by reference to a copy of the
Amended and Restated Note (the form of which is attached hereto
as Exhibit 10.1).
Item 1.02 Termination of a Material Definitive
Agreement.
The Amended and Restated Note has superseded the Old Note, which
is no longer in effect. The information set forth under Item 1.01
above is incorporated by reference into this Item 1.02.
Item 2.03 Creation of a Direct Financial Obligation or an
Obligation under an Off-Balance Sheet Arrangement of a
Registrant.
The information set forth under Item 1.01 above is incorporated
by reference into this Item 2.03.
Item 9.01 Financial Statements and Exhibits.
|
|
(d) |
Exhibits. |
|
10.1 Amended and Restated Promissory Note, executed on December 27, 2016, made by ERBA Diagnostics, Inc. in favor of Citibank, N.A. |
About Diagnostics, Inc. (NYSE:DGX)
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Company’s Diagnostic Information Services business develops and delivers diagnostic testing information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, employers and others. The Company’s Diagnostic Solutions offers a range of solutions for insurers and healthcare providers. The Company provides risk assessment services for the life insurance industry. In addition, the Company offers healthcare organizations and clinicians’ health information technology solutions and diagnostic products. ExamOne provides risk assessment services to the life insurance industry in North America. ChartMaxx is the Company’s enterprise content management system for hospitals. Diagnostics, Inc. (NYSE:DGX) Recent Trading Information
Diagnostics, Inc. (NYSE:DGX) closed its last trading session up +0.03 at 91.90 with 737,685 shares trading hands.
